Scared off Sequenom

Sequenom stock falls on possible fundraising ahead of Down's Syndrome data

Sequenom Inc. (NASDAQ:SQNM) shareholders got cold feet last week after the company said on its earnings call that it will need to raise money this year - and that it will not necessarily wait for data from its SEQureDx Down Syndrome test to do so.

On the week,

Read the full 472 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE